Atypical Antipsychotic Treatment of Disruptive Behavior Disorders in Children and Adolescents
J Clin Psychiatry 2008;69(suppl 4):9-14
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Disruptive behavior disorders, including conduct disorder, oppositional
defiant disorder, and disruptive behavior disorder not otherwise specified,
are serious conditions in children and adolescents that include a behavior
pattern of violating the basic rights of others and age-appropriate rules or
standards and may include aggressive behavior. Although no pharmacotherapy is
currently approved for use in this population, evidence suggests that atypical
antipsychotic treatment may be useful in patients with these conditions who
present with problematic aggression. Currently, research on risperidone shows
it to be effective in treating aggressive behavior in this patient population.
Limited research is also available on olanzapine, quetiapine, and aripiprazole,
but more research is needed on these and other agents. As with any
pharmacotherapy, adverse events (including weight gain, headache, and
somnolence) should be carefully considered with these medications, especially
in children and adolescents, and it is important to properly dose and monitor
patients during medication therapy.